| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 用于修饰脂肪酶的方法 | CN201580024454.5 | 2015-05-26 | CN106459936A | 2017-02-22 | A.V.赖泽; V.K.巴蒂亚; K.博尔奇; C.I.约恩森; B.安德森; L.鲍恩斯加德 |
| 本发明涉及用于修饰脂肪酶的一个或多个特征的方法，该方法包括使肽与脂肪酶结合的步骤，其中该肽与所述脂肪酶的前肽的至少一个主要脂肪酶接触区的氨基酸序列具有至少50％序列一致性。 | ||||||
| 2 | 脂膜白蛋白纳米颗粒组合物以及制备和使用其的方法 | CN201380033165.2 | 2013-05-23 | CN104582691A | 2015-04-29 | R·J·李 |
| 公开了脂质纳米颗粒制剂、制备和使用其的方法。 | ||||||
| 3 | 脂质纳米颗粒组合物以及制备和使用其的方法 | CN201380033174.1 | 2013-05-23 | CN105163721A | 2015-12-16 | R·J·李 |
| 公开了脂质纳米颗粒制剂，制备和使用其的方法。 | ||||||
| 4 | 一种蛋白酶K及其应用 | CN201310088128.3 | 2013-03-19 | CN104059900A | 2014-09-24 | 王华明; 林艳梅 |
| 本发明涉及一种蛋白酶K及其应用，所述的一种蛋白酶K的核苷酸序列为SEQ ID NO：2，氨基酸序列为SEQ ID NO：1。本发明筛选出的蛋白酶K切割脂族氨基酸和芳香族氨基酸的羧基端肽键，可以用来制备脉冲电泳的染色体DNA,蛋白印迹以及去除DNA和RNA制备中的核酸酶，也可以用于提取组织中非蛋白成份降解含有蛋白质的杂志，比如DNA疫苗和肝素的制备等，具有工业生产应用价值。而且筛选出的蛋白酶K基因可以用来转化工程菌，从而获得具有表达蛋白酶K的重组菌。 | ||||||
| 5 | 一种重组布氏白僵菌蛋白酶K及其工业化生产与纯化方法 | CN201410472748.1 | 2014-09-16 | CN104232611A | 2014-12-24 | 李旭; 滕脉坤 |
| 本发明公开了一种重组布氏白僵菌蛋白酶K及其工业化生产与纯化方法，涉及基因改造和蛋白质工程技术领域，通过生物信息手段得到适于毕赤酵母重组表达的重组白僵菌蛋白酶K编码基因，合成该优化基因并在真核系统表达成功，得到了酶活明显大于传统林伯氏白色念球菌蛋白酶K的重组蛋白酶K，并提供了该重组白僵菌蛋白酶K的工业化生产与纯化方法。本发明通过化学合成该编码基因并构建GS115/pPIC9K-ProK高产工程菌，克服了天然产品产量低、费用高的缺陷，并显著降低了相关产业的蛋白酶K使用成本，具有广泛的应用前景。 | ||||||
| 6 | ENZYME-FUNCTIONALISED NANOBEADS FOR ANTI-BIOFOULING PURPOSES | US15761359 | 2016-09-16 | US20180343872A1 | 2018-12-06 | Michelle ZANONI; Jessica AMADIO; Eoin CASEY; Olivier HABIMANA |
| A composition comprising a silica-based nanobead having its surface functionalized by a moiety selected from moieties that are reactive to and combine with a fouling layer on a material surface. | ||||||
| 7 | Lipid Nanoparticle Compositions and Methods of Making and Methods of Using the Same | US15689667 | 2017-08-29 | US20180021447A1 | 2018-01-25 | Robert J. Lee |
| Lipid nanoparticle formulations, methods of making, and methods of using same are disclosed. | ||||||
| 8 | SYSTEMS, METHODS AND KITS FOR EXTRACTING NUCLEIC ACID FROM DIGESTIVE FLUID | US14798021 | 2015-07-13 | US20160010081A1 | 2016-01-14 | Hatim T. Allawi; Graham P. Lidgard |
| Provided herein is technology relating to isolating and/or extracting DNA from gastric fluid samples, e.g., pancreatic juice samples. In particular, the technology relates to methods, reagents, and kits for isolating DNA from stimulated pancreatic juice samples, for use, e.g., in methylation and mutation analyses. | ||||||
| 9 | Therapeutic for treating Clostridium difficile infection | US14402389 | 2013-05-08 | US09205133B2 | 2015-12-08 | Lisa Dawson; Brendan Wren |
| The invention relates to deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a pharmaceutical or veterinary composition or formulation comprising at least deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a combination therapeutic comprising at least deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a method of treating a mammal suspected of being infected with, or infected with, C. difficile comprising the use of at least deoxyribonuclease; a method of cleaning or sterilizing a material or product comprising the use of at least deoxyribonuclease; and a cleaning or sterilizing product impregnated with or containing at least deoxyribonuclease. | ||||||
| 10 | STABILIZED PROTEASE-CONTAINING SOLUTIONS | US13276553 | 2011-10-19 | US20120100597A1 | 2012-04-26 | Steven T. Okino; Yan Wang |
| The present invention provides compositions and methods for purifying RNA-free DNA from a sample. | ||||||
| 11 | Dispersinb, 5-Fluorouracil, Deoxyribonuclease I and Proteinase K-Based Antibiofilm Compositions and Uses Thereof | US12935982 | 2009-04-03 | US20110086101A1 | 2011-04-14 | Srinivasa Madhyastha; Purusbottam Gawande; Karen Lovetri; Nandadeva Yakandawala; Jeffrey Kaplan |
| The present invention provides antibiofilm composition comprising two or more agents selected from the group consisting of DispersinB™, 5-Fluorouracil, Deoxyribonuclease I and Proteinase K for preventing growth and proliferation of biofilm-embedded microorganisms in wound care, oral care, and disease-related infections and methods of treatment in mammals. The invention further provides methods for preparing medical devices, and wound care devices using an antibiofilm composition comprising two or more antimicrobial agents selected from the group consisting of DispersinB™, 5-Fluorouracil, Deoxyribonuclease I and Proteinase K. | ||||||
| 12 | 脂質コートされたアルブミンナノ粒子組成物と、それを作製する方法、及びそれを使用する方法 | JP2015514193 | 2013-05-23 | JP6228191B2 | 2017-11-08 | リー,ロバート・ジェイ |
| 13 | アンチセンスオリゴヌクレオチドを送達するための脂質ナノ粒子組成物 | JP2015514189 | 2013-05-23 | JP6220389B2 | 2017-10-25 | ロバート ジェイ.リー; ヤング ボク リー; テグ ジュン キム; チャン ホー アン |
| 14 | アンチセンスオリゴヌクレオチドを送達するための脂質ナノ粒子組成物 | JP2015514189 | 2013-05-23 | JP2015519346A | 2015-07-09 | ジェイ．リー ロバート; ボク リー ヤング; ジュン キム テグ; ホー アン チャン |
| 重合体に結合した巨大分子とターゲティング剤とを含む脂質ナノ粒子組成物が記載される。組成物は、治療剤を含みうる。治療剤は、アンチセンスオリゴヌクレオチド(ASO)でありうる。例示的なASOは、Akt−1をコードする核酸の一部をターゲティングし、Akt−1の発現を調節するか、またはHIF−1をコードする核酸の一部をターゲティングし、HIF−1の発現を調節する。また、重合体に結合した巨大分子と、Akt−1をコードする核酸の一部をターゲティングし、Akt−1の発現を調節するASO、またはHIF−1をコードする核酸の一部をターゲティングし、HIF−1の発現を調節するASOなどのASOである治療剤とを含む脂質ナノ粒子組成物も記載される。また、医薬処方物、脂質ナノ粒子を作製する方法、および、例えば、がんを処置するために脂質ナノ粒子を使用する方法も開示される。 | ||||||
| 15 | A METHOD FOR MODIFYING A LIPASE | EP15724304.9 | 2015-05-26 | EP3149159B1 | 2018-11-14 | REISER, Anna Verena; BHATIA, Vikram Kjoeller; BORCH, Kim; JOERGENSEN, Christian I.; ANDERSEN, Birgitte; BAUNSGAARD, Lone |
| The present invention relates to a method for modifying one or more characteristics of a lipase, comprising the step of associating a peptide to the lipase, wherein the peptide has at least 50% sequence identity with the amino acid sequence of at least one major lipase contact zone of the propeptide of said lipase. | ||||||
| 16 | LIPID NANOPARTICLE COMPOSITIONS FOR ANTISENSE OLIGONUCLEOTIDES DELIVERY | EP13726404.0 | 2013-05-23 | EP2852415A1 | 2015-04-01 | LEE, Robert, J.; LEE, Young, Bok; KIM, Deog, Joong; AHN, Chang, Ho |
| Described is a lipid nanoparticle composition that includes a macromolecule conjugated to a polymer and a targeting agent. The composition can include a therapeutic agent. The therapeutic agent can be an antisense oligonucleotide (ASO). Exemplary ASOs are targeted to a portion of a nucleic acid encoding Akt-1, and which modulates the expression of Akt-1; or targeted to a portion of a nucleic acid encoding HIF-1, and which modulates the expression of HIF-1. Also described is a lipid nanoparticle composition that includes a macromolecule conjugated to a polymer and a therapeutic agent that is an ASO such as an ASO targeted to a portion of a nucleic acid encoding Akt-1, and which modulates the expression of Akt-1 or an ASO targeted to a portion of a nucleic acid encoding HIF-1, and which modulates the expression of HIF-1. Pharmaceutical formulations, methods of making the lipid nanoparticles, and methods of using the lipid nanoparticles, for example for treating cancers, are also disclosed. | ||||||
| 17 | THERAPEUTIC FOR TREATING CLOSTRIDIUM DIFFICILE INFECTION | EP13725423.1 | 2013-05-08 | EP2852402A1 | 2015-04-01 | DAWSON, Lisa; WREN, Brendan |
| The invention relates to deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a pharmaceutical or veterinary composition or formulation comprising at least deoxyribonucleasefor use in the treatment of a suspected or existing C. difficile infection; a combination therapeutic comprising at least deoxyribonucleasefor use in the treatment of a suspected or existing C. difficile infection; a method of treating a mammal suspected of being infected with, or infected with, C. difficile comprising the use of at least deoxyribonuclease; a method of cleaning or sterilising a material or product comprising the use of at least deoxyribonuclease; and a cleaning or sterilising product impregnated with or containing at least deoxyribonuclease. | ||||||
| 18 | Compositions and Methods for Protecting Plants Against Bacterial Infections | US15412420 | 2017-01-23 | US20180208938A1 | 2018-07-26 | Goutam Gupta |
| A method of creating a genetically altered plant and parts thereof with a chimeric protein comprising a first domain, a second domain, and a third domain, wherein said first domain comprises either i) a recognition element comprising a Proteinase K sequence, or BPI/LBP sequence, or ii) a lysis element comprising a thionin sequence, said second domain comprises either i) a recognition element comprising a sequence selected from Proteinase K sequence, or BPI/LBP sequence, or ii) a lysis element comprising a thionin sequence wherein the second domain is an element that is different from the element of the first domain and said third domain comprises a linker; wherein said linker separates said first domain from said second domain such that said first domain and said second domain can each fold into its appropriate three-dimensional shape and retains its activity. | ||||||
| 19 | ENZYMATIC DEBRIDEMENT THERAPY FOR ABNORMAL CELL PROLIFERATION | US14267395 | 2014-05-01 | US20170020996A1 | 2017-01-26 | JAMES A. LIVINGSTON |
| Compositions and methods are provided to destroy internal cancerous lesions selectively by the administration of a combination of a debridement protease enzyme and a denaturant of cell structural proteins and or cell adhesion proteins. | ||||||
| 20 | THERAPEUTIC FOR TREATING CLOSTRIDIUM DIFFICILE INFECTION | US14932669 | 2015-11-04 | US20160058846A1 | 2016-03-03 | Lisa Dawson; Brendan Wren |
| The invention relates to deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a pharmaceutical or veterinary composition or formulation comprising at least deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a combination therapeutic comprising at least deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a method of treating a mammal suspected of being infected with, or infected with, C. difficile comprising the use of at least deoxyribonuclease; a method of cleaning or sterilising a material or product comprising the use of at least deoxyribonuclease; and a cleaning or sterilising product impregnated with or containing at least deoxyribonuclease. | ||||||
QQ群二维码
意见反馈
意见反馈